Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

Status

Active, not recruiting

NCT ID

NCT06519097

This is a randomized, double-blind, placebo-controlled trial, investigating whether treatment with δ-tocotrienol (a.k.a. Delta-tocotrienol, abbreviated as DT3) will prevent the progression of Intraductal Papillary Mucinous Neoplasm (IPMN) of the pancreas.

Intervention

Placebo, Vitamin E Delta Tocotrienol

Condition

Neoplasm of Pancreas, IPMN, Pancreatic

Investigators

Mokenge P Malafa, MD, FACS

See list of participating sites